pharma · Myotonic Dystrophy type 1 and type 2 (DM1/DM2) · Non-Dystrophic Myotonias (NDM)
Lupin (Europe)
Lupin Europe GmbH
Lupin (Europe) patent portfolio — 0 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
EU HQ
37 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Employees
- 37
- Programs
- 4
- Drugs
- 9
- Patents
- 0
Lupin (Europe) patents
0 pharmaceutical patents indexed for Lupin (Europe). 0 expire within 24 months.
Lupin (Europe) has 0 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
No patents matched
Frequently asked questions
How many patents does Lupin (Europe) have?
0 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Lupin (Europe) patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.